Neuroprotection in Alzheimer's Disease offers a translational point-of-view from both basic and clinical standpoints, putting it on the cusp for further clinical development with its emphasis on nerve cell protection, including the accumulation of knowledge from failed clinical trials and new advances in disease management.
This book brings together the latest findings, both basic, and clinical, under the same cover, making it easy for the reader to obtain a complete overview of the state-of-the-field and beyond. Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. It is a progressive brain disease that slowly destroys memory, thinking skills, and eventually, even the ability to carry out the simplest tasks. It is characterized by death of synapses coupled to death nerve cells and brain degeneration which is manifested by loss of cognitive abilities. Understanding neuroprotection in Alzheimer's disease will pave the path to better disease management and novel therapeutics.
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science Publishing Co Inc
Zielgruppe
Maße
Höhe: 229 mm
Breite: 152 mm
Gewicht
ISBN-13
978-0-12-803690-7 (9780128036907)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Dr. Illana Gozes is a Professor Emerita at the Sackler Faculty of Medicine and is a faculty of the Sagol School of Neuroscience and Adams Super Center for Brain Studies at Tel Aviv University in Tel Aviv, Israel. She is the incumbent of the Lily and Avraham Gildor Chair for the Investigation of Growth Factors and Heads the Elton Laboratory for Molecular Neuroendocrinology. Prof. Gozes won many awards of excellence (including Bergmann Award, Fogarty-Scholar-in-Residence, Tel Aviv University's Vice President Award-best applied scientist, Olson Prize, Julodan Prize, Teva Prize, Neufeld Award, Hanse-Wissenschaftskolleg (HWK) fellowship, Humboldt Award, Landau Prize for Life Achievements and Champion of Hope - Science International -2016, Global Genes, USA. She is an Ex-President of the Israel Society for Neuroscience, served on the Governing Committee and the Board of Governors of Tel Aviv University, and is currently serving on the Council of the European Society for Neurochemistry, the Israeli Ministry of Education, Council of Higher Education and is the Israeli coordinator of the International Brain Bee Competition for high school students and the Editor-in-Chief of the Journal of Molecular Neuroscience and serves on many journal editorial boards. Professor is the inventor of numerous patents including CP201(NAP, davunetide), a clinical drug candidate targeted at the rare disease indication, the ADNP syndrome (founded Allon Therapeutics and currently Chief Scientific Officer at Coronis Neurosciences). Professor Gozes discovered ADNP, an essential protein for brain formation implicated in autism, schizophrenia, Alzheimer's disease and cancer. CP201 is a snippet of ADNP, enhancing ADNP's protective activity. Professor Gozes published >320 papers and has an h-index of 73 (Google Scholar).
Herausgeber*in
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel
1. Introduction
2. Neural regeneration as a disease modifying therapeutic strategy for Alzheimer's disease
3. Animal models
4. Mechanisms of Neuronal Microtubule Loss in Alzheimer's Disease
5. Tau-centric therapies for treating Alzheimer's Disease
6. The potential of small molecules in preventing tau oligomers formation and toxicity
7. A novel neuroprotection target with distinct regulation in stroke and Alzheimer?s disease
8. Sirtuin modulation as novel neuroprotective strategy for Alzheimer's Disease
9. Rescue of neurons by resolving inflammation
10. Targeting transition metals for neuroprotection in Alzheimer's disease
11. Multifunctional effect of human serum albumin towards neuroprotection in Alzheimer disease
12. RGS2 and SIRT1 link renin angiotensin aldosterone system to Alzheimer's disease
13. Neuroprotective drug development: the story of ADNP, NAP (davunetide) and SKIP
